BioPharmSignal logoBioPharmSignal

Biotech News

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel (BTAI)BioXcelEarnings

FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the

Open original release

Related news

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

RLAYRelay Therapeutics2026-05-05 20:05 EST

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ARGXArgenx2026-05-07 05:00 EST

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

BioXcel

BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.

Recent company news

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BTAIBioXcel2026-04-17 11:00 EST

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BTAIBioXcel2026-04-08 11:00 EST

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BTAIBioXcel2026-04-01 11:00 EST

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Stock data

Close
0.87 USD
Market cap
36.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States